Table 4.
Adverse events frequency and duration after first and second Full and Half Dose of ChAdOx1 nCov-19.
| Adverse Event (%) | Full dose (n = 154) | Half dose (n = 558) | ||||
|---|---|---|---|---|---|---|
| 1st dose (%) | 2nd dose (%) | Duration (days) | 1st dose (%) | 2nd dose (%) | Duration (days) | |
| Overall | 84 | 57 | – | 83 | 52 | – |
| Pain on injection local | 77 | 59 | 4.5 | 69* | 34* | 3.1** |
| Headache | 51 | 37 | 3.7 | 50 | 21* | 2.5* |
| Malaise | – | – | – | 47 | 25 | 2.3* |
| Tiredness | 43 | 28 | 4.6 | 41 | 16 | 2.9 |
| Chills | – | – | – | 37 | 18 | 1.9 |
| Muscle pain | 35 | 24 | 9.3 | 36 | 14 | 2.9** |
| Joint pain | 19 | 7 | 14.1 | 30* | 12* | 2.9** |
| Fever | 17 | 14 | 1.7 | 23 | 8 | 1.7 |
| Nausea | 17 | 6 | 3.9 | 17 | 8 | 2.0 |
| Local hardening | – | 10 | 3.5 | 31 | 16* | 3.1 |
| Local edema | 14 | 17 | 4.6 | 24 | 12 | 2.5 |
| Redness | 10 | 11 | 2.4 | 13 | 8* | 3.0 |
| Vomiting | 1 | 0 | 1.0 | 2 | 1 | 2.4 |
Full dose, ChAdOx1 Full dose group; Half dose, ChAdOx1 Half dose group. *p < = 0.05 **p < = 0.001.